Brussels – The European Commission today (17 November) granted marketing authorisation to the marketing authorisation for Daraxonrasib in the European Union, a new anti-tumour medicine for metastatic pancreatic cancer. The medicine may be used to treat adult patients who have already undergone at least one previous course of treatment. In line with the EU’s pharmaceutical reform, the medicine underwent accelerated regulatory procedures, without compromising the “Union’s rigorous standards of safety, quality, and efficacy.” This involved a streamlined review by the European Medicines Agency (EMA), which issued a positive scientific assessment in just over 100 days. This is almost half the time required under the previous legal deadline of 210 days. The newly authorised medicine could address what has been described as “an unmet medical need,” as it targets a serious disease for which better treatment options are required. For this reason, it has been designated a “high-priority medicine” under the EMA’s Cancer Medicines Pathfinder programme, which, launched in 2023, focuses on patient care and access to innovative therapies.
Daraxonrasib is also the subject of an ongoing
joint clinical assessments
(JCA) by the Member States’ Co-ordination Group on Health Technology Assessment. These assessments enable EU Member States to collaborate in evaluating the clinical benefits of new medicines and certain medical devices, thereby reducing duplication, saving time and resources, and providing companies with a clearer and more predictable process. At present, work on the JCA report is being fast-tracked to make it available in December, in order to facilitate its access across the Union. The JCAs were established by Regulations on the assessment of health technologies (HTA) with the aim of supporting Member States’ national health technology assessment processes by providing a scientific analysis of the clinical evidence relating to the effects of a health technology (a medicinal product or a medical device) on health outcomes.
English version by the Translation Service of Withub







